Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | SQLE | Q14534 | 8/20 | 0.81 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | FNTA | P49354 | 1/20 | 0.59 |
| ▸ | FNTB | P49356 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Squalene SCHEMBL31125292 | 1.00 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| Squalene SCHEMBL4444267 | 1.00 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| Squalene SCHEMBL2799805 | 1.00 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| Squalene SCHEMBL890053 | 1.00 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| Squalene SCHEMBL8819997 | 1.00 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL8013144 | 1.00 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL23802597 | 1.00 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL21639794 | 1.00 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| Squalene SCHEMBL21823197 | 1.00 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| Squalene SCHEMBL29525662 | 1.00 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103211920-B | Callicarpa kwangtungensis chun. low-polarity ingredient extract, pharmaceutical composition containing Callicarpa kwangtungensis chun. low-polarity ingredient extract, preparation method and application | SHANGHAI INST PHARM INDUSTRY | 2014-12-17 | — | — | CN | claimed |
| WO-2013144595-A1 | PERIDININ-CHLOROPHYLL BINDING PROTEINS | PROTEIN TECHNOLOGIES LIMITED (GB) | 2013-10-03 | — | — | WO | claimed |
| CN-103211920-A | Callicarpa kwangtungensis chun. low-polarity ingredient extract, pharmaceutical composition containing Callicarpa kwangtungensis chun. low-polarity ingredient extract, preparation method and application | SHANGHAI INST PHARM INDUSTRY | 2013-07-24 | — | — | CN | claimed |
| US-20260144834-A1 | ANTIMICROBIAL FEED ADDITIVE | Axitan Ltd. (GB) | 2026-05-28 | — | — | US | disclosed |
| US-20260123660-A1 | Particles Containing a Lipid Matrix Core and Active Ingredient | LONZA SALES AG (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4054348-B1 | PARTICLES CONTAINING A LIPID MATRIX CORE AND ACTIVE INGREDIENT | LONZA SALES AG (CH) | 2026-01-28 | — | — | EP | disclosed |
| US-12471609-B2 | Reducing the risk of viral infection due to viral contaminated feed | NOVUS INTERNATIONAL, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12465075-B2 | Particles containing a lipid matrix core and active ingredient | LONZA SALES AG (CH) | 2025-11-11 | — | — | US | disclosed |
| EP-4642253-A1 | USE OF MICROALGAE AND MICROALGAE DERIVED COMPONENTS IN CULTIVATED FOOD PRODUCTION | Weforesea Ltd. (IL) | 2025-11-05 | — | — | EP | disclosed |
| US-12458623-B2 | Low-grade inflammation compositions | CYTOSOLVE, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250281440-A1 | METHOD TO IMPROVE GROWTH PERFORMANCE, LIVABILITY, CARCASS CHARACTERISTICS AND/OR MILK QUALITY IN SWINE | NUTRIQUEST, LLC | 2025-09-11 | — | — | US | disclosed |
| US-20050059635-A1 | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels | CARDAX PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| US-20050059659-A1 | Carotenoid analogs or derivatives for controlling C-reactive protein levels | CARDAX PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| US-20050049248-A1 | Carotenoid ether analogs or derivatives for controlling C-reactive protein levels | CARDAX PHARMACEUTICALS, INC. | 2005-03-03 | — | — | US | disclosed |
| US-20050037995-A1 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury | CARDAX PHARMA, INC. | 2005-02-17 | — | — | US | disclosed |
| US-20050026874-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| US-20050009930-A1 | Carotenoid analogs or derivatives for controlling connexin 43 expression | CARDAX PHARMA, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20050009788-A1 | Carotenoid ester analogs or derivatives for controlling connexin 43 expression | CARDAX PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20050009758-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMA, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20050004235-A1 | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037995-A1 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury | CPT1A, TXNRD2, PC | KMT2A 4784/4885SQLE 87/4885MAPT 4758/4885 |
| US-20260144834-A1 | ANTIMICROBIAL FEED ADDITIVE | ELOVL6, CROCC, ELOC | KMT2A 4102/4885SQLE 2216/4885MAPT 3063/4885 |
| US-20250281440-A1 | METHOD TO IMPROVE GROWTH PERFORMANCE, LIVABILITY, CARCASS CHARACTERISTICS AND/OR MILK QUALITY IN SWINE | PIGS, GLO1, IGFBP6 | KMT2A 1476/4885SQLE 3725/4885MAPT 3007/4885 |
| US-20050009788-A1 | Carotenoid ester analogs or derivatives for controlling connexin 43 expression | GJA1, GJB2, CRY1 | KMT2A 4411/4885SQLE 73/4885MAPT 4813/4885 |
| US-20050009930-A1 | Carotenoid analogs or derivatives for controlling connexin 43 expression | GJA1, GJB2, CRY1 | KMT2A 4274/4885SQLE 82/4885MAPT 4766/4885 |
| US-20050059635-A1 | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels | TTPA, PROC, RBP4 | KMT2A 4495/4885SQLE 122/4885MAPT 3857/4885 |
| US-20050059659-A1 | Carotenoid analogs or derivatives for controlling C-reactive protein levels | RBP1, PROC, RBP4 | KMT2A 4236/4885SQLE 180/4885MAPT 3997/4885 |
| US-20050026874-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease | GYS2, HCCS, CPT1A | KMT2A 3761/4885SQLE 40/4885MAPT 3961/4885 |
| US-20260123660-A1 | Particles Containing a Lipid Matrix Core and Active Ingredient | AUP1, MGLL, MBOAT4 | KMT2A 3977/4885SQLE 191/4885MAPT 440/4885 |
| US-20050049248-A1 | Carotenoid ether analogs or derivatives for controlling C-reactive protein levels | PROC, TTPA, CYC1 | KMT2A 3858/4885SQLE 367/4885MAPT 4035/4885 |
| US-20050009758-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease | NFE2L2, GPX4, CYP11B2 | KMT2A 3613/4885SQLE 63/4885MAPT 4360/4885 |
| US-20050004235-A1 | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease | GYS2, HCCS, CPT1A | KMT2A 3942/4885SQLE 19/4885MAPT 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.